Stocks and Investing
Stocks and Investing
Tue, August 1, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ed Arce Reiterated (CDTX) at Strong Buy and Held Target at $120 on, Aug 1st, 2023
Ed Arce of HC Wainwright & Co., Reiterated "Cidara Therapeutics, Inc." (CDTX) at Strong Buy and Held Target at $120 on, Aug 1st, 2023.
Ed has made no other calls on CDTX in the last 4 months.
There is 1 other peer that has a rating on CDTX. Out of the 1 peers that are also analyzing CDTX, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $60 on, Friday, May 12th, 2023
Contributing Sources